Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Trotman

Showing results (81-90 of 148) with videos related to

Pageof 15
Sort By:
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
The New England Journal of Medicine|June 2, 2018
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's MacroglobulinemiaMeletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Blood Advances|October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphomaPaola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2023
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma RiskMichael K Odutola, Marina T van Leeuwen, Fiona Bruinsma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2015
Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et alSally F Barrington, N George Mikhaeel, Lale Kostakoglu, et al.
Blood Advances|April 9, 2024
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancyZoe K McQuilten, Robert Weinkove, Le Thi Phuong Thao, et al.
Annals of Hematology|July 11, 2023
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphomaGrzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.
Blood Advances|September 3, 2024
Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG studyEmma Verner, Amanda Johnston, Nalini Pati, et al.
Pageof 15

Showing results (81-90 of 148) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
The New England Journal of Medicine|June 2, 2018
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's MacroglobulinemiaMeletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Blood Advances|October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphomaPaola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2023
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma RiskMichael K Odutola, Marina T van Leeuwen, Fiona Bruinsma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2015
Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et alSally F Barrington, N George Mikhaeel, Lale Kostakoglu, et al.
Blood Advances|April 9, 2024
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancyZoe K McQuilten, Robert Weinkove, Le Thi Phuong Thao, et al.
Annals of Hematology|July 11, 2023
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphomaGrzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.
Blood Advances|September 3, 2024
Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG studyEmma Verner, Amanda Johnston, Nalini Pati, et al.
Pageof 15